Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Rating Lowered by Zacks Research

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Thursday,Zacks.com reports.

Several other research firms have also recently commented on KNSA. Weiss Ratings raised Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. Canaccord Genuity Group increased their price target on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research report on Wednesday. Wedbush lifted their price objective on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an “outperform” rating in a research note on Wednesday. Citigroup boosted their price objective on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 12th. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $87.38.

Kiniksa Pharmaceuticals International Stock Down 4.9%

Shares of KNSA stock opened at $74.34 on Thursday. The firm has a 50 day moving average of $59.04 and a two-hundred day moving average of $51.13. The stock has a market capitalization of $5.72 billion, a PE ratio of 76.64 and a beta of 0.07. Kiniksa Pharmaceuticals International has a 52 week low of $29.90 and a 52 week high of $82.94.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.30. The business had revenue of $243.60 million for the quarter, compared to analyst estimates of $226.49 million. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. Analysts expect that Kiniksa Pharmaceuticals International will post 1.38 EPS for the current fiscal year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, Director G Bradley Cole sold 3,673 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total transaction of $299,092.39. Following the completion of the sale, the director directly owned 11,672 shares of the company’s stock, valued at $950,450.96. The trade was a 23.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 51.98% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently made changes to their positions in the business. KBC Group NV purchased a new stake in Kiniksa Pharmaceuticals International during the first quarter worth approximately $34,000. Smartleaf Asset Management LLC purchased a new position in Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $36,000. EverSource Wealth Advisors LLC increased its stake in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares during the last quarter. Nano Cap New Millennium Growth Fund L P acquired a new stake in Kiniksa Pharmaceuticals International during the fourth quarter worth approximately $41,000. Finally, CIBC Private Wealth Group LLC acquired a new stake in Kiniksa Pharmaceuticals International during the fourth quarter worth approximately $41,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.